Juan W. Valle, MB ChB, MSc, FRCP

On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference.

On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.

Dr Lewis Roberts discusses molecular biomarkers that may correlate with known epidemiological risk factors associated with the incidence of cholangiocarcinoma, and the types of preclinical and clinical studies that are needed to explore these correlations.

Drs Juan Valle and Angela Lamarca discuss clinical studies being conducted to improve the use of chemotherapy in CCA by exploring molecular biomarkers that could help patient selection for optimal response to certain chemotherapy regimens.

Cholangiocarcinoma (CCA) is a cancer arising from the intra- or extra-hepatic bile ducts, mainly characterized by its late diagnosis and fatal outcome. Painless obstructive jaundice is a common presenting symptom and managing the malignant biliary obstruction to ensure adequate drainage is necessary to effectively treat both cholangiocarcinoma and a subset of pancreatic cancer patients (those with disease in the head of the pancreas).